Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The SURMOUNT-1 trial for tirzepatide showed average weight loss of 15% of starting body weight at 36 weeks (roughly 8.5 months)
We understand that life can be busy, so we offer flexible scheduling options to accommodate your needs
Cagrilintide vs AOD 9604 Mechanism: Cagrilintide: Amylin receptor agonist (appetite/satiety) AOD 9604: HGH fragment (fat metabolism) Completely different Weight loss: Cagrilintide: 10-12% body weight AOD 9604: 5-8% body weight (less robust data) Cagrilintide superior Clinical evidence: Cagrilintide: Extensive Phase 2/3 trials AOD 9604: Limited clinical data Cagrilintide better studied Side effects: Cagrilintide: GI effects common AOD 9604: Minimal side effects AOD 9604 better tolerated Combination potential: Could theoretically combine (different mechanisms) No clinical data on combination Cagrilintide + semaglutide better established Verdict: Cagrilintide more powerful, better evidence
She is just as professional as she is sweet
US$ 29.36
US$ 26.92
US$ 24.13
US$ 25.81
US$ 26.59
US$ 22.66
US$ 20.70
US$ 26.20
